Chronic (1 year) treatment with an endothelin receptor antagonist greatly improves survival in the hamsters with heart failure doe to cardiomyopathy: Increased expression of endothelin-1 mRNA in the failing heart of cardiomyopathic hamsters

被引：0
|
作者：
Miyauchi, T
Yamauchi, R
Kobayashi, T
Hoshino, T
Sakai, S
Kikkawa, K
Yabana, H
Murata, S
Goto, K
Sugishita, Y
机构：
[1] Univ Tsukuba, Tsukuba, Ibaraki 305, Japan
[2] Tanabe Seiyaku Co Ltd, Toda, Saitama, Japan
来源：
CIRCULATION | 1998年 / 98卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
415
引用
收藏
页码：82 / 82
页数：1
相关论文
共 35 条
  • [21] Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure
    Sakai, S
    Miyauchi, T
    Yamaguchi, I
    CIRCULATION, 2000, 101 (24) : 2849 - 2853
  • [22] Contribution of endogenous endothelin-1 to the progression of right-sided heart failure caused by pulmonary hypertension in rats: Improvement of survival and of failing right ventricular gene expression by chronic treatment
    Miyauchi, T
    Sato, R
    Sakai, S
    Kobayashi, T
    Ueno, M
    Kondo, H
    Kawano, S
    Goto, K
    Yamaguchi, I
    CIRCULATION, 1999, 100 (18) : 272 - 272
  • [23] Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure:: A 7-year follow-up study
    van Beneden, R
    Gurné, O
    Selvais, PL
    Ahn, SA
    Robert, AR
    Ketelslegers, JM
    Pouleur, HG
    Rousseau, MF
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (06) : 490 - 495
  • [24] Rational pharmacotherapy of chronic heart failure with increased endothelin-1 activity: beta-adrenoblocker nebivolol place
    Olbinskaya, L. I.
    Naymann, Yu. I.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2007, 6 (01): : 61 - 67
  • [25] Acute hemodynamic and renal effects of the endothelin-1 receptor antagonist TAK-044 in patients without heart failure
    Sutsch, G
    Fleisch, M
    Yan, XW
    Wenzel, R
    Binggeli, C
    Bianchetti, MC
    Kiowski, W
    Luscher, T
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (02) : 52132 - 52132
  • [26] Results of a randomized, placebo-controlled, hemodynamic trial with an intravenous endothelin-1 receptor antagonist in patients with congestive heart failure
    Torre-Amione, G
    Durand, JB
    Bozkurt, B
    Vooletich, MT
    Young, JB
    Pratt, CM
    Charlon, V
    Widman, T
    CIRCULATION, 1999, 100 (18) : 647 - 647
  • [27] Effects of a specific endothelin-1A (ETA) receptor antagonist on the development of chronic heart failure (HF) in the dog.
    McConnell, PI
    Wang, W
    Gallagher, K
    Zucker, IH
    FASEB JOURNAL, 1996, 10 (03): : 2485 - 2485
  • [28] Clinical and hemodynamic effects of an orally active endothelin-1-receptor antagonist in patients with refractory chronic heart failure.
    Suetsch, G
    Christen, S
    Yan, XW
    Strobel, W
    Rickenbacher, P
    Hunziker, P
    Bertel, O
    Kiowski, W
    CIRCULATION, 1997, 96 (08) : 511 - 511
  • [29] Amelioration of altered expression of various cardiac genes in the failing heart by chronic endothelin inhibitor treatment is involved in great improvement in long-term survival in rats with chronic heart failure
    Sakai, S
    Miyauchi, T
    Kobauashi, T
    Yamaguchi, I
    Goto, K
    Sugishita, Y
    CIRCULATION, 1997, 96 (08) : 3514 - 3514
  • [30] Atrial natriuretic peptide compensates for the attenuated brain natriuretic peptide response to increased endothelin-1 production in patients with chronic heart failure
    Yousufuddin, M
    Henein, M
    Flather, M
    Shamim, W
    Al-Nasser, F
    Kemp, M
    Hooper, J
    Banner, NR
    Amrani, M
    Coats, AJS
    EUROPEAN HEART JOURNAL, 2001, 22 : 502 - 502
1234